151 related articles for article (PubMed ID: 32493335)
1. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial.
Ferreira JP; Mehta C; Sharma A; Nissen SE; Rossignol P; Zannad F
BMC Med; 2020 Jun; 18(1):165. PubMed ID: 32493335
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
[TBL] [Abstract][Full Text] [Related]
3. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
[TBL] [Abstract][Full Text] [Related]
4. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
[TBL] [Abstract][Full Text] [Related]
5. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
Cavender MA; White WB; Jarolim P; Bakris GL; Cushman WC; Kupfer S; Gao Q; Mehta CR; Zannad F; Cannon CP; Morrow DA
Circulation; 2017 May; 135(20):1911-1921. PubMed ID: 28246236
[TBL] [Abstract][Full Text] [Related]
6. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
[TBL] [Abstract][Full Text] [Related]
8. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
[TBL] [Abstract][Full Text] [Related]
9. Effects of alogliptin in chronic kidney disease patients with type 2 diabetes.
Sakai Y; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Otsuka T; Ohno D; Murasawa T; Tsuruoka S
Intern Med; 2014; 53(3):195-203. PubMed ID: 24492687
[TBL] [Abstract][Full Text] [Related]
10. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
Cavender MA; White WB; Liu Y; Massaro JM; Bergenstal RM; Mehta CR; Zannad F; Heller S; Cushman WC; Cannon CP
Clin Cardiol; 2018 Aug; 41(8):1022-1027. PubMed ID: 29652078
[TBL] [Abstract][Full Text] [Related]
11. Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
Keating GM
Drugs; 2015 May; 75(7):777-96. PubMed ID: 25855222
[TBL] [Abstract][Full Text] [Related]
12. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
Sharma A; Cannon CP; White WB; Liu Y; Bakris GL; Cushman WC; Zannad F
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29769203
[TBL] [Abstract][Full Text] [Related]
13. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Mann JFE; Fonseca V; Mosenzon O; Raz I; Goldman B; Idorn T; von Scholten BJ; Poulter NR
Circulation; 2018 Dec; 138(25):2908-2918. PubMed ID: 30566006
[TBL] [Abstract][Full Text] [Related]
14. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
Shimada YJ; Cannon CP; Liu Y; Wilson C; Kupfer S; Menon V; Cushman WC; Mehta CR; Bakris GL; Zannad F; White WB;
Am Heart J; 2016 May; 175():18-27. PubMed ID: 27179720
[TBL] [Abstract][Full Text] [Related]
15. Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Scott LJ
Drugs; 2010 Oct; 70(15):2051-72. PubMed ID: 20883057
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
White WB; Pratley R; Fleck P; Munsaka M; Hisada M; Wilson C; Menon V
Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301
[TBL] [Abstract][Full Text] [Related]
17. Alogliptin benzoate for management of type 2 diabetes.
Saisho Y
Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
[TBL] [Abstract][Full Text] [Related]
18. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
Hwang YC; Morrow DA; Cannon CP; Liu Y; Bergenstal R; Heller S; Mehta C; Cushman W; Bakris GL; Zannad F; White WB
Diabetes Obes Metab; 2018 Mar; 20(3):654-659. PubMed ID: 29064626
[TBL] [Abstract][Full Text] [Related]
19. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
Bergmark BA; Cannon CP; White WB; Jarolim P; Liu Y; Bonaca MP; Zannad F; Morrow DA
Diabetes Obes Metab; 2017 Jul; 19(7):962-969. PubMed ID: 28195387
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
DeFronzo RA; Fleck PR; Wilson CA; Mekki Q;
Diabetes Care; 2008 Dec; 31(12):2315-7. PubMed ID: 18809631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
